Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBT (2016 - 2025)

Historic EBT for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $18.9 million.

  • Veracyte's EBT rose 1211.42% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 47951.29%. This contributed to the annual value of $25.7 million for FY2024, which is 13360.31% up from last year.
  • Per Veracyte's latest filing, its EBT stood at $18.9 million for Q3 2025, which was up 1211.42% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's EBT registered a high of $18.9 million during Q3 2025, and its lowest value of -$45.7 million during Q1 2021.
  • Over the past 5 years, Veracyte's median EBT value was -$8.3 million (recorded in 2023), while the average stood at -$7.4 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 78555.65% in 2023, then surged by 48930.82% in 2025.
  • Quarter analysis of 5 years shows Veracyte's EBT stood at -$11.3 million in 2021, then surged by 69.59% to -$3.4 million in 2022, then crashed by 785.56% to -$30.5 million in 2023, then surged by 111.3% to $3.4 million in 2024, then skyrocketed by 448.62% to $18.9 million in 2025.
  • Its EBT was $18.9 million in Q3 2025, compared to $1.2 million in Q2 2025 and $7.4 million in Q1 2025.